INSULIN GLARGINE 300U/ML AND INSULIN GLARGINE 100U/ML SHOW EQUIPOTENT IN VIVO BLOOD GLUCOSE LOWERING WHEN ADMINISTERED INTRAVENOUSLY IN DOGS

被引：0
|
作者：
Werner, U. [1 ]
Korn, M. [1 ]
Tennagels, N. [1 ]
机构：
[1] Sanofi, Diabet Div, Frankfurt, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
296
引用
收藏
页码：A119 / A119
页数：1
相关论文
共 50 条
  • [21] Is Hypoglycemia a Modifiable Patient Risk in Type 2 Diabetes? A Pooled Analysis of Insulin Glargine 300U/mL (Gla-300) vs. 100U/mL (Gla-100) Trials
    Rosenstock, Julio
    Zhang, Quanwu
    Gerrits, Charles
    Liao, Laura
    Chew, Paul
    [J]. DIABETES, 2015, 64 : A110 - A110
  • [22] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [23] COMPARISON OF INSULIN GLARGINE 300 U/ML, INSULIN DEGLUDEC AND INSULIN GLARGINE 100 U/ML, IN BASAL INSULIN THERAPY USING FREESTYLE LIBRE PRO: RANDOMISED TRIPLE CROSSOVER STUDY
    Takeishi, S.
    Tsuboi, H.
    Takekoshi, S.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A137 - A137
  • [24] Insulin glargine 300 U/ml versus Insulin degludec 100 U/ml Direct Comparison of long-acting Insulins
    Stiefelhagen, Peter
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2019, 12 (01): : 38 - 38
  • [25] Adjustment of insulin doses when switching from glargine 100U/ml or detemir to degludec: an observational study
    Lualdi, C.
    Silverii, A.
    Dicembrini, I.
    Pala, L.
    Monami, M.
    Mannucci, E.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (03) : 319 - 326
  • [26] New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Ziemen, M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 386 - 394
  • [27] Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
    Bolli, Geremia B.
    Cheng, Alice
    Charbonnel, Bernard
    Aroda, Vanita R.
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Boelle-Le Corfec, Emmanuelle
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1588 - 1593
  • [28] In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
    Schiavon, Michele
    Visentin, Roberto
    Giegerich, Clemens
    Sieber, Jochen
    Dalla Man, Chiara
    Cobelli, Claudio
    Klabunde, Thomas
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) : 553 - 561
  • [29] Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus
    Linari, Guido
    Fleeman, Linda
    Gilor, Chen
    Giacomelli, Lucia
    Fracassi, Federico
    [J]. JOURNAL OF FELINE MEDICINE AND SURGERY, 2022, 24 (02) : 168 - 176
  • [30] Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
    Lindauer, Klaus
    Becker, Reinhard
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (01) : 1 - 10
12345